SQUARE
e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL. 15     ISSUE: 7  July 2017 Medical Services Department

SQUARE Pharmaceuticals Ltd.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

MAHFUZUR RAHMAN

 MBBS, MBA

MD. Saiful Alam

 MBBS, MPH

 

EDITORIAL

Dear Doctor:

Welcome to 'e-SQUARE' !

Our current issue focused on some features like

"Dementia in Head Injury !", "Probiotics & Infection !", "Opioids Threat in COPD !", "Vaccine & Gonorrhea !", "Cooling Cap in Cancer !", "Asthma in Pregnancy !".

In our regular feature, we have some new products information of SQUARE Pharmaceuticals Ltd. as well.

Please send us your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE PHARMACEUTICALS LTD.

Dementia in Head Injury !

Severe Head Injury May Raise Dementia Risk Years Later

A severe head injury, especially during middle age, could dramatically boost the risk for developing dementia later in life, new research from Finland suggests. The investigation tracked dementia risk among people who had suffered a traumatic brain injury [TBI] at 65 or younger. Ultimately, the lead researcher determined that not only did the risk go up for those who had a TBI, but the worse the initial head injury, the greater the risk of dementia. The study showed that 3.5 percent of persons with moderate-to-severe TBI were diagnosed with a neurodegenerative disease later in life. This is substantially higher compared to age-matched peers with no history of brain injury. By comparison, only 1.6 percent of persons with mild TBI were diagnosed with a neurodegenerative disease. The study authors pointed out that this research could only show an association; it could not prove a direct cause-and-effect link between traumatic brain injury and dementia. In addition, a traumatic brain injury was only linked to a higher risk for developing dementia, not to a higher risk for other neurological conditions, such as Parkinson's or ALS. The American Association of Neurological Surgeons (AANS) says that about 1.7 million Americans experience some form of traumatic brain injury each year, often resulting from a fall, a car accident or a firearm accident. Among moderate-to-severe traumatic brain injury patients, roughly one in three ends up succumbing to their injury, the lead researcher noted. One in two survivors end up struggling with lifelong disabilities. The AANS pegs the number of Americans living with a TBI-induced disability at more than 5 million. The new study included more than 40,000 Finnish adults between 18 and 65 who had been hospitalized with mild, moderate or severe traumatic brain injuries. The injuries occurred between 1987 and 2014. The researchers followed the study participants for about 11 years. The roughly 20,000 mild TBI patients were hospitalized for less than a day. None had experienced a traumatic brain lesion such as brain bruising, swelling, bleeding or a blood clot. More than 20,000 moderate-to-severe traumatic brain injury patients had been hospitalized for a minimum of three days. All had been diagnosed with some form of serious brain lesion. There was no significant difference between the two groups in terms of age, educational background or income. Though above-average dementia risk was seen among all TBI patients, the moderate-to-severe group faced a substantially higher risk than the mild group. The largest jump in risk was seen among those who had a traumatic brain injury between ages 41 and 50. Their odds of dementia were nearly triple those of someone with a mild injury. For those who had a TBI between ages 51 and 60, the odds of dementia were doubled, the study showed. More people in the moderate-to-severe group also ended up with dementia before the age of 65, compared to those in the mild group (40 percent versus 26 percent, respectively). Thus, until we have a specific treatment for this, it is extremely important to minimize other risk factors for dementia, such as high blood pressure, high levels of cholesterol, diabetes, tobacco smoking and alcohol consumption, the lead researcher added .

SOURCE: HealthDay News, July 2017

Return to top

Probiotics & Infection !

Probiotic Supplements Failed to Prevent Babies' Infections

Probiotic supplements may not protect babies from catching colds or stomach bugs in day care, a new clinical trial suggests. Probiotic supplements provide some of those same organisms. Most often, products contain strains of the bacteria Lactobacillus and Bifidobacterium, according to the U.S. National Institutes of Health. Among 290 babies in child care, those given probiotics every day for six months were no less likely to suffer respiratory or gastrointestinal infections, the lead investigator found. The findings stand in contrast to some past studies: Specifically, two trials have found that probiotics cut the risk of gastrointestinal infections among babies in child care. The reasons for the conflicting results aren't clear. But child health experts said it may have to do with breast-feeding. Many babies in the current study were breast-fed, which in itself helps ward off infections. It's possible any benefit from the probiotics was overshadowed by the known protective effects of breast-feeding, said by lead researcher. Breast milk contains human milk oligosaccharides, which are in unique combinations in the breast milk from each mother. Oligosaccharides are compounds that act as "prebiotics" -- helping to spur the growth of specific bacteria in the baby's digestive tract. So breast-feeding, rather than probiotic supplements, might be the best way to encourage a healthy balance of gut bacteria. The study included Danish infants between the ages of 8 months and 14 months who were going into child care. Researchers randomly assigned the babies to two groups. In one, parents were given a probiotic powder to mix in with baby food or liquid once a day; parents in the other group were given a placebo powder. There was no difference between the two groups in absences from child care over the next six months, the study found. The average number of days missed was 11 for both groups. And based on parents' daily reports, there were no differences in cold symptoms, diarrhea, fever or vomiting. But almost half of the babies were still being breast-fed, and they were all in good health, said by lead researcher.

SOURCE: HealthDay News, July 2017

Return to top

 
 
 Opioids Threat in COPD !

Opioids a Threat to Seniors With COPD

A progressive lung disease that causes breathing problems may increase their odds for heart-related death if they use opioid painkillers, a new study finds. COPD patients are often prescribed opioids, including morphine and fentanyl. These narcotics can help treat chronic muscle and bone pain, insomnia, persistent cough and shortness of breath despite inhaler use, the lead researcher explained. Previous research has shown about 70 percent of older adults with COPD use opioids, which is an incredibly high rate of new use in a population that is potentially more sensitive to narcotics. Our new findings show there are not only increased risks for coronary artery disease-related death associated with new opioid use, but also increased risk of cardiac-related visits to emergency rooms and hospitalizations. For the study, the lead researcher examined data from 144,000 COPD patients, aged 66 and older, in Canada. The researchers found that new opioid use was associated with a 215 percent increase in coronary artery disease-related death among long-term care patients compared to those not taking the prescription painkillers. Among patients living at home, the difference was 83 percent. Two-thirds of the long-term care patients and 60 percent of the patients who lived at home were given a new opioid between April 2008 and March 2013, the lead researcher added. Opioids pose heart risks because they can lower blood-oxygen levels and increase blood-carbon dioxide levels. They also can increase inflammatory factors in the blood vessels, leading to blockages that can cause a heart attack. One other important reason might be linked to future risk of heart attacks is because they offer pain relief, which could reduce or take away chest pain that acts as a warning before a cardiac event. Without that warning, doctors may not be able to intervene in time. However, the study did not prove a cause-and-effect link between the drugs and heart risks, just an association.

SOURCE: HealthDay News, July 2017

Return to top

 
 
Vaccine & Gonorrhea !

New Hope in Search for Vaccine against Gonorrhea

A vaccine to protect people from the sexually transmitted disease gonorrhea may be one step closer to reality, New Zealand researchers report. That's welcome news, because gonorrhea appears to be eluding treatment efforts to control the disease. Antibiotics are the only available treatment, but strains of antibiotic-resistant gonorrhea have developed, according to U.S. health officials. Despite efforts, a gonorrhea vaccine with any clinical effect has eluded development for over 100 years, said by lead researcher. We have found a vaccine that prevented about one-third of gonorrhea in those who received it in a real-life situation. It is far from perfect, but it is a leap in the right direction. Called MeNZB vaccine, it was developed to control a meningitis epidemic in New Zealand from 2004 to 2006 and is no longer available. But the antigens in the vaccine thought to provide the immune response to gonorrhea are included in the more recently developed 4CMenB vaccine, which is available in many countries, the lead researcher added. The researchers found that people who had been vaccinated with the MeNZB vaccine were less likely to have gonorrhea than those who weren't. We followed up the observation that gonorrhea rates appeared to drop in association with the use of this type of meningococcal B vaccine and found that indeed the vaccine had a protective effect against gonorrhea for a period of time after its use. About one-third of those vaccinated were protected, lead researcher said. After taking into account factors such as race, sex, socioeconomics and geographical area, the researchers calculated that vaccination reduced the odds of getting gonorrhea by 31 percent. In the United States, teens and preteens, as well as some children and adults, are advised to get one of two meningococcal vaccines to protect against meningitis. Whether the current meningococcal vaccines would protect against gonorrhea still needs to be tested. Modeling has suggested that even a vaccine with quite a modest level of effectiveness could have a significant impact on gonorrhea over the period of fifteen years or so. If gonorrhea goes untreated or is treated late, it can have a long-term health impact," the lead researcher explained. Untreated, it can lead to complications such as pelvic inflammatory disease, ectopic pregnancy and infertility, and it can make the transmission of HIV more likely. Approximately 78 million new cases of gonorrhea are seen worldwide each year.

SOURCE: HealthDay News, July 2017

Return to top

 

 
Cooling Cap in Cancer !

FDA Widens Access to 'Cooling Cap' to Stop Hair Loss in Cancer Patients

More cancer patients may be able to ward off hair loss during chemotherapy treatment. A cooling cap approved in 2015 for use in breast cancer patients has won expanded approval from the U.S. Food and Drug Administration. The DigniCap Cooling System can now be used for patients with solid tumors, the FDA announced. The computer-controlled cap contains liquid that circulates and cools the scalp, narrowing blood vessels. This reduces how much of the chemotherapy drugs reach hair follicle cells, the FDA said. Cooling also decreases activity of hair follicles and slows cell division. The result: Chemo drugs don't affect them as much, according to the FDA. Hair loss is a common side effect of chemotherapy, especially during treatment of most solid tumor cancers. Hair may fall out all at once, little by little or become thin. We are pleased to expand the use of this product for cancer patients with solid tumors to potentially minimize chemotherapy-induced hair loss. Managing the side effects of chemotherapy is a critical component to overall health and quality of life- FDA news release. But the cap isn't for everyone. It may not work with some treatment regimens. And it should not be used on children, patients with certain cancers, and those having specific kinds of chemotherapy, the FDA said. In addition, the agency said, the cap may be not be suited for patients with cold sensitivity or susceptibility to cold-related injuries. Common side effects of the cap include cold-induced headaches, neck and shoulder discomfort, chills and pain. Wearing it is not likely to cause chemotherapy drugs to miss some cancer cells in the scalp, according to the FDA. However, the long-term effects of scalp-cooling and risk of cancer spread have not been fully studied, the FDA added.

SOURCE: HealthDay News, July 2017

Return to top

 
Asthma in Pregnancy !

Asthma Control Essential in Pregnancy, Study Suggests

Children whose mothers had uncontrolled asthma during pregnancy are at increased risk of developing the disease at a young age, a new study finds. The findings suggest that "maintaining asthma control during pregnancy is an area for possible prevention of asthma in future generations, lead author said. Researchers analyzed data from nearly 7,200 children in Denmark who were born to mothers with active asthma during pregnancy. Those born to mothers who had mild controlled asthma were less likely to be diagnosed with asthma at an early age than those whose moms had mild uncontrolled asthma, moderate-to-severe controlled asthma, or moderate-to-severe uncontrolled asthma during pregnancy, the study found. The study was published online July 13 in the Journal of Allergy and Clinical Immunology. Asthma is one of the most common chronic diseases in pregnant women. In most cases, they should manage the respiratory condition through the use of medication in the same way as women who aren't pregnant, according to the study authors. However, they noted that previous research indicates that one-quarter of women with asthma don't take prescribed asthma medications during pregnancy, and rates of poor inhaler technique range from 41 to 54 percent. Poor asthma control is a risk factor "that potentially can be targeted in clinical practice and intervened upon.

SOURCE: HealthDay News, July 2017

Return to top

 
 

New Products of SQUARE Pharmaceuticals Ltd.

  Product PrazolokTM 1
  Generic Name Prazosine HCl
  Strength 1 mg
  Dosage form Tablet
  Therapeutic Category Antihypertensive
  Product PrazolokTM 2
Generic Name Prazosine HCl
Strength 2 mg
Dosage form Tablet
Therapeutic Category Antihypertensive
  Product NexumTM 40 MUPS
  Generic Name Esomeprazole
  Strength 40 mg
  Dosage form Tablet
  Therapeutic Category Antiulcerant

Return to top

 

Copyright 2017 SQUARE Pharmaceuticals Ltd. All rights reserved